Details of the Target
General Information of Target
Probe(s) Labeling This Target
ABPP Probe
Probe name | Structure | Binding Site(Ratio) | Interaction ID | Ref | |
---|---|---|---|---|---|
FBPP2 Probe Info |
![]() |
7.05 | LDD0318 | [1] | |
OPA-S-S-alkyne Probe Info |
![]() |
K328(1.99); K76(2.54) | LDD3494 | [2] | |
DBIA Probe Info |
![]() |
C323(2.84) | LDD3313 | [3] | |
BTD Probe Info |
![]() |
C323(1.39) | LDD2101 | [4] | |
Curcusone 37 Probe Info |
![]() |
2.91 | LDD0188 | [5] | |
m-APA Probe Info |
![]() |
H140(0.00); H221(0.00) | LDD2231 | [6] | |
IA-alkyne Probe Info |
![]() |
C298(0.00); C323(0.00) | LDD0165 | [7] | |
NAIA_5 Probe Info |
![]() |
C392(0.00); C323(0.00) | LDD2223 | [8] |
PAL-AfBPP Probe
Competitor(s) Related to This Target
Competitor ID | Name | Cell line | Binding Site(Ratio) | Interaction ID | Ref |
---|---|---|---|---|---|
LDCM0632 | CL-Sc | Hep-G2 | C392(0.38) | LDD2227 | [8] |
LDCM0033 | Curcusone1d | MCF-7 | 2.91 | LDD0188 | [5] |
LDCM0022 | KB02 | ICC108 | C323(2.66) | LDD2381 | [3] |
LDCM0023 | KB03 | ICC108 | C323(3.72) | LDD2798 | [3] |
LDCM0024 | KB05 | Hs 936.T | C323(2.84) | LDD3313 | [3] |
LDCM0508 | Nucleophilic fragment 17a | MDA-MB-231 | C323(1.39) | LDD2101 | [4] |
LDCM0518 | Nucleophilic fragment 22a | MDA-MB-231 | C323(0.77) | LDD2111 | [4] |
LDCM0530 | Nucleophilic fragment 28a | MDA-MB-231 | C323(0.63) | LDD2123 | [4] |
LDCM0534 | Nucleophilic fragment 30a | MDA-MB-231 | C323(0.99) | LDD2127 | [4] |
LDCM0541 | Nucleophilic fragment 36 | MDA-MB-231 | C323(0.68) | LDD2134 | [4] |
LDCM0542 | Nucleophilic fragment 37 | MDA-MB-231 | C323(1.54) | LDD2135 | [4] |
LDCM0543 | Nucleophilic fragment 38 | MDA-MB-231 | C323(0.96) | LDD2136 | [4] |
LDCM0544 | Nucleophilic fragment 39 | MDA-MB-231 | C323(0.69) | LDD2137 | [4] |
LDCM0546 | Nucleophilic fragment 40 | MDA-MB-231 | C323(0.91) | LDD2140 | [4] |
LDCM0554 | Nucleophilic fragment 7a | MDA-MB-231 | C323(0.88) | LDD2148 | [4] |
The Interaction Atlas With This Target
The Drug(s) Related To This Target
Phase 3
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
Trovax | Vaccine | D0L1OT | |||
Naptumomab Estafenatox | . | D0T8HR |
Phase 2
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
Cv-9201 | Vaccine | D02DVK |
Phase 1
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
Gen1044 | Antibody | DQ15HJ | |||
Pf-06263507 | Antibody | D03JZC |
Discontinued
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
Anatumomab Mafenatox | Antibody | D0W5NP |
References